Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BeBetter Med logo — Clinical-stage drug discovery and development of advanced no...

BeBetter Med

Clinical-stage drug discovery and development of advanced novel medicines for cancer and other severe illnesses.

Founded 2012 China China 5 employees Private Equity Total: $499.00M Health Care, Pharmaceutical

General Information

Company Name BeBetter Med
Founded Year 2012
Location China China +1
Employees 5
Industries Health Care, Pharmaceutical
Funding Stage Private Equity
Social

Get notified when BeBetter Med moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BeBetter Med

BeBetter Med is a rapidly growing novel drug discovery and development company based in Guangzhou, China. Founded in 2012 by overseas returnees, the company is dedicated to creating advanced novel medicines for the treatment of cancer and other severe diseases. With a focus on clinical-stage drug discovery and development, BeBetter Med has positioned itself as a strong contender in the Health Care and Pharmaceutical industries. The company boasts a robust pipeline with eight innovative drug candidates, all with proprietary intellectual property rights. Notably, BEBT-908 has progressed to the pivotal phase II trial for the treatment of lymphoma, while BEBT-209 and BEBT-109 are in the phase Ib/II trial for breast cancer and lung cancer, respectively. This demonstrates BeBetter Med's commitment to tackling a varied spectrum of severe illnesses with its comprehensive pharmaceutical research capabilities extending from drug design and synthesis to clinical development. In November 2019, the company received a Venture Round investment from Lucky Source Funds, signifying external validation and support for its vision and capabilities. This investment underscores the confidence of industry stakeholders in BeBetter Med's potential to bring several new drugs to the market in the coming years. With a strong foundation and a promising portfolio, BeBetter Med presents an intriguing opportunity for investors seeking to participate in the advancement of cutting-edge treatments for critical medical conditions.

Taxonomy: drug discovery, clinical-stage, novel medicines, cancer treatment, pharmaceutical research, oncology drugs, metabolic disease, clinical development, small molecule drugs, clinical trials, IP rights, Guangzhou, biopharmaceutical company, overseas returnees

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round •••••• 2
Investor Investor
08 Oct 2021
Venture Round •••••• 2
Investor
•••• •••• 		15 Nov 2019

BeBetter Med Alternatives & Competitors

BeBetter Med vs
Enterome
Enterome France

Delivering the promise of immunotherapy

Series Unknown
49 employees
Biopharma, Biotechnology
Compare BeBetter Med vs Enterome
BeBetter Med vs
Himuka AM Pharma / Himuka AM Australia
Himuka AM Pharma / Himuka AM Australia Japan

Himuka is a clinical-stage biotech company, and conducting a Phase 1 clinical trial in Australia.

Corporate Round
1 employees
Digital Health, Health Care
BeBetter Med vs
Molecular Templates
Molecular Templates United States

Engineering the Next Generation of Therapeutics

Post Ipo Equity
26 employees
Biotechnology, Health Care

FAQ About BeBetter Med

Clinical-stage drug discovery and development of advanced novel medicines for cancer and other severe illnesses.
BeBetter Med was founded in 2012.
BeBetter Med is headquartered in China.
BeBetter Med operates in the following industries: Health Care, Pharmaceutical.
BeBetter Med has approximately 5 employees.
BeBetter Med has completed 2 funding rounds, raising a total of $499.00M. The latest funding stage is Private Equity.
Top alternatives and competitors to BeBetter Med include Enterome, Himuka AM Pharma / Himuka AM Australia, Molecular Templates, Natsar Pharmaceuticals, Inspirna, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BeBetter Med and Enterome are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BeBetter Med and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy